FDA approves drug for treating rare type of non-Hodgkin lymphoma

On July 3, the U.S. Food and Drug Administration (FDA) approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma, a rare and fast-growing type of non-Hodgkin lymphoma. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here